Cargando…
The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab
BACKGROUND: Immunogenicity due to antidrug antibodies (ADA) to tumor necrosis factor (TNF)-α antagonists is known to decrease treatment response. However, few studies have investigated ADA in ustekinumab, an interleukin-12 and -23 antagonist, in a clinical setting. This study aimed to investigate th...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Public Library of Science
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643875/ https://www.ncbi.nlm.nih.gov/pubmed/26566272 http://dx.doi.org/10.1371/journal.pone.0142930 |